MedTrace Logo

Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)

NCT01122615 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2015-11-18

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of sunitinib and temsirolimus that can be given to patients with metastatic kidney cancer.

Conditions

Interventions

DRUG

Sunitinib

12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle.

DRUG

Temsirolimus

6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Nizar M. Tannir, MD · UT MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01122615 on ClinicalTrials.gov